

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10EL820014677US
Express Mail Label NumberOctober 18, 2001
Date of DepositIN THE UNITED STATES PATENT AND TRADEMARK OFFICE #13

IN RE APPLICATION OF

DIGAN ET AL.

APPLICATION NO: 09/480,236

FILED: JANUARY 10, 2000

FOR: ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES
THEREFORAssistant Commissioner for Patents
Washington, D.C. 20231

Art Unit: 1643

Examiner: Ewoldt, G.

TECH CENTER 1600/2900

OCT 22 2001

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

It is noted that EP 669,316 is in French; however, it includes a set of claims in English. As stated in the previously submitted IDS, EP 669,316 is a substantial equivalent of US Patent 5,637,613.

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180.00 for payment of the fee required by 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge the above-mentioned \$180.00 fee and any additional fees which may be required to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,



Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6765

Date: October 18, 2001

Encls.: additional copy of this paper
PTO 1449 form